3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
12
Carcinoma, Non-Small-Cell Lung
3
Prostatic Neoplasms, Castration-Resistant
2
Primary Myelofibrosis
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumours
1
Small Cell Lung Carcinoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Metastatic Castration-resistant Prostate Cancer
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Interventions
Fluorouracil
4
Radiotherapy
3
Mitomycin
3
Surveys and Questionnaires
2
Observation
2
Cisplatin
2
tempol
1
rocakinogene sifuplasmid
1
pembrolizumab
1
fludarabine
1
enzalutamide
1
durvalumab
1
abiraterone
1
Vorinostat
1
VGX-3100
1
Therapeutics
1
Taxes
1
Specimen Handling
1
Psychiatric Rehabilitation
1
Palonosetron
1
Paclitaxel
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
MEDI0457
1
Ipilimumab
1
Interviews as Topic
1
Interleukin-2
1
Immunoglobulin G
1
Genetic Testing
1
Disulfides
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Anus Neoplasms
×
abiraterone
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts